Neobloc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neobloc

Quick Facts

Property Description
Active Ingredient Metoprolol (tartrate or succinate)
Forms Immediate-Release (IR) and Extended-Release (ER) Oral Tablets, Injectable Solution
Pharmacological Class Beta-Adrenergic Receptor Antagonist (Beta-Blocker)
Common Use Principle Reduces cardiac workload and oxygen demand
Origin Synthetic, single-ingredient compound

What Type of Medicine is Neobloc?

Neobloc is a prescription medication whose active ingredient is Metoprolol, officially classified as a Beta-Adrenergic Receptor Antagonist, commonly known as a Beta-Blocker. This compound is a synthetic, single-ingredient derivative designed to selectively block the effects of stress hormones, primarily adrenaline, on the heart's specialized beta-1 receptors. This cardioselective action means Metoprolol preferentially targets the heart, which differentiates it from older, non-selective Beta-Blockers that also affect receptors in other tissues, such as the lungs. Metoprolol's primary function is modulating the heart's response to hormonal stimulation.


Composition and Available Forms of Metoprolol

The Metoprolol substance is prepared using two primary salt forms—Metoprolol tartrate and Metoprolol succinate—which determine the drug’s release profile and subsequent therapeutic schedule. The tartrate form is typically used in Immediate-Release (IR) Oral Tablets and requires multiple daily administrations. Conversely, the succinate form is engineered for extended action and is available in Extended-Release (ER) Oral Tablets or capsules, allowing for once-daily dosing to provide consistent therapeutic levels over 24 hours. Metoprolol's succinate salt is crucial for extended-release formulations to ensure a round-the-clock effect. Both oral forms are available, and Metoprolol tartrate also has an Injectable Solution preparation for intravenous use in specific clinical settings.


Neobloc's Core Purpose: Reducing Cardiac Workload

The fundamental purpose of Neobloc is to help stabilize cardiovascular function by limiting the degree of cardiac stimulation caused by stress hormones. By blocking the beta-1 receptors, Metoprolol reduces the rate at which the heart beats (negative chronotropic effect) and decreases the force of each contraction. This collective physiological action serves to lower the heart muscle's overall workload and reduce its demand for oxygen, which is the general benefit achieved by the medication to promote stable and efficient cardiac performance over time. A common application of this principle is assisting in the long-term stabilization of patients who have experienced a previous cardiac event.

Regulatory References

  1. U.S. National Library of Medicine
  2. National Institutes of Health (NIH)

What side effects are possible with Neobloc?

Possible Side Effects and Safety Information

The safety profile for Neobloc (Metoprolol) is organized by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. The official labeling highlights distinct categories of risks, ranging from the most commonly reported effects to rare, serious adverse events and specific constraints on use.

Officially Documented Adverse Reactions

Classification Aspect Official Regulatory Description
Most Common Reactions Tiredness, dizziness, bradycardia (abnormally slow heart rate), shortness of breath, low blood pressure (hypotension), pruritus (itching), and rash are frequently listed in regulatory documents.
System-Organ Classes Adverse effects are documented across the Cardiovascular system (e.g., cold extremities, palpitations), the Nervous System (e.g., depression, headache), and the Gastrointestinal system (e.g., diarrhea, nausea).

Serious Adverse Reactions and Constraints

The label identifies clinically significant risks, including the potential worsening of existing heart failure (decompensation) and the risk of myocardial ischemia or infarction if long-term therapy is abruptly stopped. The medication is officially contraindicated (should not be used) in the presence of severe pre-existing cardiac conditions, such as severe bradycardia, second- or third-degree heart block, cardiogenic shock, and decompensated heart failure.

Population-Specific Safety Notes

Because the drug is extensively metabolized by the liver, official safety notes recommend using lower starting doses and exercising caution in patients with hepatic impairment. Additionally, safety and effectiveness have not been established in the pediatric population under six years of age. Treatment may also mask the symptoms of hyperthyroidism or hypoglycemia, which is an important consideration in regulatory safety assessments.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Metoprolol (Neobloc) overdose emphasizes immediate and severe physiological manifestations requiring urgent professional intervention. Suspected overdose is associated with severe suppression of cardiac function, resulting from excessive beta-blockade.

Documented Overdose Manifestations and Outcomes

Classification Manifestations and Outcomes (as stated in official documents)
Clinical Signs Severe bradycardia (slow heart rate), marked hypotension (low blood pressure), dizziness, and bronchospasm
Life-Threatening Outcomes Cardiogenic shock, asystole (cardiac arrest), coma, convulsions, and respiratory depression

Immediate Medical Attention is Required: Any suspected Neobloc overdose is considered a medical emergency. Regulatory labeling explicitly mandates that patients seek immediate medical attention or contact emergency services immediately due to the potential for life-threatening events.

Official Management Statements: No specific antidote is known for Metoprolol overdose. Management procedures listed in official documents focus on symptomatic and supportive treatment, which may include gastric lavage, administration of activated charcoal, and pharmaceutical interventions such as atropine or high-dose Glucagon. Continuous ECG monitoring and observation in an intensive care setting are often required.

Therapeutic Uses of Neobloc

The core therapeutic applications of Neobloc (Metoprolol) involve long-term supportive management in conditions marked by increased physiological stress, such as high blood pressure (hypertension) and chronic stable chest pain (angina pectoris). The medication may support managing symptoms linked to organ-specific functional stress, which is commonly used to help with managing the potential for serious cardiovascular events and may assist with maintaining functional stability by easing anginal episodes.

This medication is applied in clinical settings following a heart attack (myocardial infarction) and for patients managing chronic heart failure to assist with maintaining functional stability. This use supports the patient during difficult episodes and assists with maintaining stability in the long term, and may contribute to easing the overall symptom load associated with worsening heart failure. Indications commonly addressed include hypertension, chronic angina, atrial fibrillation and other fast, irregular heart rhythms, heart failure, and the prophylaxis of migraine headaches.

“The medication is commonly used to help with managing symptom fluctuations and supports patients during difficult episodes related to heightened physiological activity.”

Neobloc addresses symptoms related to heightened physiological activity, such as palpitations and fast, irregular heart rhythms, which helps address symptom clusters that may become intense or disruptive and easing symptomatic discomfort. Furthermore, it is relevant in non-cardiac domains as a prophylactic therapy to support patients during difficult episodes related to migraine headaches.

Quick Fact Relief for
Primary Focus Symptoms related to systemic imbalance or functional stress
Episodic Relief Supports easing the frequency of anginal chest pain
Prophylaxis Assists with managing episodic migraine manifestations

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Neobloc? — Official Regulatory Information

The eligibility profile for Neobloc (Metoprolol) is strictly defined by cardiovascular stability and certain pre-existing conditions, as documented in official regulatory labeling.

Contraindications (Must Not Use)

Use is absolutely prohibited in patients with:

  • Known hypersensitivity to metoprolol or other beta-blockers.
  • Severe, uncontrolled heart failure (decompensated).
  • Cardiogenic shock or low blood pressure (systolic BP <100 mmHg for certain acute indications).
  • Severe bradycardia (very slow heart rate) or unpaced second- or third-degree heart block.

Special Population Restrictions and Limitations

Population Group Eligibility Status Restriction Basis
Pediatric Patients Not recommended below 6 years of age. Safety and effectiveness are not established.
Severe Liver Impairment Requires caution and dosage adjustment Drug clearance is significantly reduced.
Bronchospastic Disease Generally avoided Risk of exacerbating bronchospasm; use only if necessary and with caution.
Pregnancy/Lactation Use only if benefit outweighs risk Metoprolol crosses the placenta and is found in breast milk; neonates may require monitoring.

These constraints ensure the medicine is reserved for eligible populations by prohibiting its use when acute cardiac risk is high or when physiological clearance is severely compromised.

What should I know about interactions with other medicines?

The official regulatory profile for Neobloc (Metoprolol) is defined by documented interactions across pharmacokinetic, pharmacodynamic, and administrative domains.

Official Interaction Statements

  • Exposure Modification: Co-administration with strong CYP2D6 inhibitors—a category including certain antiarrhythmics and antidepressants—is documented to significantly increase metoprolol plasma concentration, often by several-fold. This increase in exposure is formally stated to diminish the drug’s inherent cardioselectivity. Conversely, enzyme inducers like Rifampicin may reduce metoprolol exposure.
  • Pharmacodynamic Reinforcement: Additive cardiovascular effects occur with drugs that independently slow heart rate or atrioventricular conduction, such as Digitalis glycosides and certain calcium channel blockers (Diltiazem, oral Verapamil). Co-use may result in an increased risk of bradycardia and enhanced hypotensive effects with other blood pressure-lowering drugs.
  • Administrative Constraints: The use of Intravenous Verapamil is explicitly restricted in patients receiving metoprolol due to the documented risk of severe cardiac events. A mandatory withdrawal sequence is also required for Clonidine: metoprolol must be withdrawn several days prior to the gradual discontinuation of Clonidine to mitigate the risk of rebound hypertension.
  • Substance Interactions: The co-ingestion of Alcohol (Ethanol) is documented to result in higher and slower-clearing blood alcohol levels. Additionally, Non-steroidal Anti-inflammatory Drugs (NSAIDs) may impair the antihypertensive effect.

Connection to the Overall Interaction Profile

Regulatory documents structure the interaction profile by classifying substances that directly alter metoprolol clearance via the CYP2D6 enzyme system and those that produce additive physiological effects. This framework establishes specific constraints, including a prohibited co-administration route and a required sequencing for drug withdrawal.

Mechanism of Action

Neobloc, containing metoprolol, functions as a beta1-adrenergic receptor antagonist. Its primary biological targets are the beta1-adrenoceptors, which are selectively expressed at high density on the cardiac tissues, including the sinoatrial (SA) node, atrioventricular (AV) node, and ventricular myocardium.

Metoprolol competitively inhibits the binding of endogenous catecholamines, such as norepinephrine and epinephrine, to these receptors. The beta1-adrenoceptors are coupled to a stimulatory G-protein (Gs), and their blockade prevents the subsequent mathrmGs activation. This halts the adenylyl cyclase pathway, reducing the intracellular conversion of ATP to cyclic adenosine monophosphate (cAMP).

Downstream, the decrease in cAMP levels leads to reduced activation of Protein Kinase A (PKA). This diminished PKA activity results in decreased phosphorylation of L-type calcium channels. The resulting reduced calcium influx into cardiac cells, particularly in the SA and AV nodes and ventricular myocytes, decreases the rate of spontaneous depolarization and the force of contraction.

System-level physiological consequences include negative chronotropy (decreased heart rate) and negative inotropy (decreased myocardial contractility), collectively leading to a reduction in cardiac output. The compound also reduces renin release from the juxtaglomerular apparatus, a beta1-mediated effect that modulates the renin-angiotensin-aldosterone system (RAAS), contributing to its overall modulatory effect on systemic arterial pressure.

Dosage and Administration Information

How to Use Neobloc

Metoprolol, the active ingredient in Neobloc, is administered through two official routes: Oral for long-term management and Intravenous (IV) for acute, monitored clinical scenarios. The selection of the dosage form determines the frequency of use. The Extended-Release (ER) succinate form is designed for once-daily dosing, providing sustained therapeutic action over 24 hours. Conversely, the Immediate-Release (IR) tartrate form requires administration in divided doses throughout the day to maintain consistent blood levels.

Dosage and Schedule Principles

Official dosing specifies ranges that vary by indication and formulation. For hypertension managed with the ER form, the typical starting dose is 25 mg to 100 mg once daily, with the dosage adjusted over weekly or longer intervals until the desired response is achieved. For patients managing chronic heart failure, the initial ER dose is lower, starting at 12.5 mg or 25 mg once daily, and slowly increased. The IV route is reserved for patients following acute myocardial infarction and involves up to three 5 mg bolus injections administered in a monitored care unit.

Administration Requirements

All oral forms of metoprolol must be taken with or immediately following a meal to ensure consistent systemic absorption. The ER tablets are scored and may be divided, but they must not be crushed or chewed. If long-term treatment is to be stopped, the dosage must be reduced gradually over a 1- to 2-week period, a procedural step required by labeling to prevent specific cardiovascular effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neobloc

Evidence for use in Chronic Insomnia

The available research primarily consists of a limited number of short-term randomized controlled trials (RCTs). Research has explored short-term symptom changes over defined time intervals, often only a few weeks. Outcomes typically monitored involved measurements of sleep parameters, such as the total time spent asleep (TST) and sleep efficiency (SE), often applied in studies examining patient-reported experiences.

Findings from these trials describe patterns observed in the studies, including measurements of small to moderate changes in outcomes related to patient-reported perceived discomfort. These reported outcomes were short-term and evidence quality varies across studies. The data show patterns related to changes in self-reported sleep measures, but the consistency of these changes findings were mixed across the small populations studied.

Evidence for use in Anxiety Disorders

Neobloc was evaluated in research exploring short-term symptom changes for conditions characterized by fluctuating or episodic manifestations, specifically various anxiety disorders. The research includes small, exploratory trials and some observational cohort studies. Researchers examined outcomes related to systemic or functional imbalance using standardized rating scales and subjective reports of perceived discomfort. The available evidence is limited and heterogeneous due to variations in study designs.

What is still uncertain about Neobloc

Key uncertainties exist across all studied indications. Long-term effects are not fully established because follow-up durations were limited in most available research. Additionally, data for certain groups remain insufficient, as the primary research base focuses on general adult populations, leaving limited information for special populations like older adults or individuals with significant co-occurring health conditions. The available evidence is limited and characterized by studies where sample sizes were modest and the need for more extensive comparative research remains.

Key Studies & References

  1. METOPROLOL tartrate NEOBLOC® - 50mg Tablet 100mg Tablet - FDA Verification Portal (Package Insert/Label)
  2. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options (Systematic Review Context)

Frequently Asked Questions (FAQ)

Common questions about Neobloc (FAQ)

Q: How quickly can I expect Neobloc to start working?

Neobloc is designed to be rapidly absorbed by the body. For the immediate-release form, the medication has an elimination half-life of approximately 3 to 7 hours, meaning consistent blood levels are generally reached over several days of continued use, as described in pharmacokinetic studies.


Q: What is the longest period of time people typically use Neobloc?

According to official regulatory documents, for the management of chronic conditions such as stable heart failure or following a myocardial infarction, the drug is generally prescribed for long-term or indefinite use to help maintain cardiovascular stability.


Q: Does Neobloc interact with medications for diabetes?

Official safety warnings indicate that this medication may mask some common symptoms of low blood sugar, such as a fast heart rate. This makes it more difficult to recognize hypoglycemia, a factor noted in official warnings for patients taking diabetes medication.


Q: How do I know if Neobloc is actually working for me?

The fundamental function of Neobloc is to slow the heart rate and lower blood pressure, which are key physiological changes. These effects are objective measures that healthcare providers monitor as part of evaluating the medication's effect.


Q: What is the purpose of the black box warning (if any) on Neobloc’s label?

Regulatory documents include a prominent warning regarding the risks associated with suddenly stopping the medication. This warning highlights the potential for serious effects, including the worsening of chest pain (angina) or the possibility of a heart attack, if the drug is abruptly discontinued.


Q: Does Neobloc need to be taken every day?

For the chronic conditions Neobloc is prescribed to manage, the medication is designed for continuous, daily use as part of a long-term treatment plan. This approach is intended to help maintain consistent blood levels for a stable effect.


Q: Is Neobloc known to cause weight gain?

Unusual or rapid weight gain is a documented, though less common, side effect of this medication. Official safety information notes that weight gain, particularly when accompanied by swelling, is a factor monitored in certain patients.


Q: Does Neobloc cause problems with sleep or insomnia?

Insomnia (trouble sleeping) and nightmares are documented adverse reactions that have been reported to the central nervous system. However, official information generally lists these as uncommon side effects.


Q: Can Neobloc affect my ability to drive or operate machinery?

The medication can cause effects like tiredness, fatigue, or dizziness, which may impair a person's cognitive functions or reactions. Official information indicates caution is needed when operating automobiles or machinery until the patient knows how they respond to the medication.


Q: What happens if I forget to take my dose of Neobloc?

Official dosing guidelines describe the procedure for a missed dose: if a dose is missed, it is generally to be taken as soon as it is remembered. However, if it is close to the next scheduled dose, the missed dose is typically skipped, and extra medicine should not be taken.


Q: Is Neobloc safe to take if I have kidney issues?

This medication is primarily cleared from the body through the liver, not the kidneys. Therefore, official labeling does not require a specific dosage adjustment for patients who have renal (kidney) impairment.


Q: What happens when a person stops taking Neobloc?

Stopping the medication suddenly can cause a rebound effect on the cardiovascular system. Official warnings state this may lead to severe effects, including the worsening of chest pain or a potential heart attack. Official labeling requires the dosage to be gradually reduced over a specified period under medical supervision.


Q: Is Neobloc used to prevent future health events?

Yes, official labeling indicates that Neobloc is used to reduce cardiovascular mortality in patients who have recently experienced an acute myocardial infarction (heart attack). It is continued long-term to help stabilize heart function and lower future risk.


Q: Can I take Neobloc with my antacids or heartburn medicine?

Co-administration with certain antacids, such as those containing calcium carbonate, may reduce the body's absorption of this medication. To help maintain consistent therapeutic levels, administration times for the two medications may need to be separated.


Q: What is the risk of a serious allergic reaction to Neobloc?

Hypersensitivity (allergy) to the drug is a contraindication, meaning it must not be used. Signs of a serious allergic reaction, such as hives, swelling of the face or throat, and difficulty breathing, require immediate emergency medical attention.


Q: How does Neobloc affect heart rate?

The core function of this medication is to cause a negative chronotropic effect, which means it slows the heart rate and decreases the force of each contraction. This combined action reduces the heart's overall workload.


Q: Is Neobloc a controlled substance?

Official scheduling from the U.S. Drug Enforcement Administration (DEA) confirms that this medication is not categorized as a controlled substance.


Q: Do I need regular blood tests while taking Neobloc?

Blood and urine tests may be required for monitoring purposes. This is partly because the medication may mask certain symptoms related to blood sugar levels or thyroid conditions, requiring lab work to check for unwanted effects.


Q: How does the time of day I take Neobloc affect its function?

Official administration requirements emphasize taking the medication at the same time each day, preferably with or immediately following a meal. This procedural consistency helps to ensure uniform systemic absorption and maintain stable blood levels throughout the treatment period.


Q: What should I look out for that might indicate a serious problem with Neobloc?

Official warnings suggest that signs of a serious problem requiring immediate reporting include an abnormally slow heartbeat, feeling lightheaded or faint, significant shortness of breath, or unexplained rapid weight gain accompanied by swelling.


Q: Can Neobloc cause changes in mood or anxiety?

Depression is a documented adverse reaction reported by the central nervous system. Changes in mood, including anxiety, are also reported as less frequent side effects according to official information.


Q: Does Neobloc cause dry mouth or changes in taste?

Dry mouth is a documented side effect reported in clinical trials and is listed as a gastrointestinal adverse reaction. Changes in taste are generally not listed among the most common adverse events.


Q: Is Neobloc safe for people who have asthma or breathing difficulties?

Patients with bronchospastic diseases, like asthma, are generally advised to avoid this class of medication. Official guidelines indicate that due to its cardioselectivity, it may be used with extreme caution and at the lowest effective dose in situations where it is considered necessary.


Q: Are headaches a common side effect of Neobloc?

Headache is a documented adverse reaction that affects the central nervous system. It is reported in official documents, but it is typically not listed among the most frequently reported side effects like tiredness or dizziness.

How should Neobloc be stored and disposed of?

How to Store and Dispose of Neobloc?

Official regulatory guidelines strictly define how Neobloc (Metoprolol) must be stored and discarded to maintain its integrity and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at a controlled room temperature, typically 20 C to 25 C.
Protection Keep the medicine in its container, tightly closed, and protected from light and excess moisture.
Child Safety It is mandatory to KEEP OUT OF REACH OF CHILDREN and out of sight.

Disposal Instructions

Disposal must follow specific regulatory protocols. Unused or expired Neobloc should be returned via a drug take-back program if one is available. If not, the medication must be prepared for household trash by mixing it with an undesirable substance (such as used coffee grounds or dirt) and sealing it in a plastic bag or container. The medicine must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neobloc found in:

A-Z Index: